Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Biomarker discovery Driving technologies" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Biomarker discovery Driving technologies for you to read. Along with our medical data and news we also list Biomarker discovery Driving technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biomarker discovery Driving technologies Companies for you to search.
Today, Philips has announced the launch of Xplore, a web-based image and data management platform that will help pharma and academic researchers speed up drug research and biomarker discovery through enhanced integration, visualization and analytics tools. Xplore v4.0 will be available commercially in July 2017. Customers have the option to purchase the basic package or ... Read More
Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.
NEW YORK & HERLEV, Denmark–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over ...
Bristol-Myers Squibb and Nordic Bioscience, a Danish company specializing in biomarker technologies, announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over 25 years’ experience in biomarker development and clinical trials with extensive ...
Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation.
Data from CMB305 and G100 to be Presented at ASCO Annual Meeting in June 2017 SEATTLE and SOUTH SAN FRANCISCO, May 17, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, reported new clinical and biomarker data today from CMB305 and G100 monotherapy studies. The American Society of Clinical Oncology (ASCO) is publishing three ab...
ReproCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery / Alliance provides wider access to oncology biospecimens to accelerate discovery and translational studies
BELTSVILLE, MD and PHILADELPHIA, PA -- (Marketwired) -- 04/13/17 -- ReproCELL and Fox Chase Cancer Center today announced a strategic alliance aimed at accelerating oncology discovery and translat...
AsiaPacific Next Generation Sequencing NGS market by Product software and services by Technology whole targeted resequencing, genome sequencing, de novo sequencing, exome sequencing, RNASeq, ChIPSeq and MethylSeqby application diagnostics, drug discove
The AsiaPacific NGS market which was worth $ 567.7 million in 2016 is poised to reach$1,636.7 million by 2021 at a CAGR of 23.59%. Asia presents significant opportunities for theinvestors/venture capitalists as the developed markets are saturated. The presence of noteworthydevelopments by China and Japan for integration of new technologies and the development ofhealthcare is majorly driving the As...
(InSilico Medicine, Inc.) Insilico Medicine, Inc, is a big data analytics company specializing in applying the latest advances in deep learning to drug discovery, biomarker development and aging research. In the NVIDIA Graphics Technology Conference (GTC), the scientists from Insilico Medicine will present its latest progress on the applications of Generative Adversarial Networks to Drug Discovery...
Life Sciences Jobs ...
Insilico Medicine, a Baltimore-based leader in artificial intelligence for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited.
Life Sciences Jobs ...
Life Sciences Jobs ...
Life Sciences Jobs ...
(InSilico Medicine, Inc.) Insilico Medicine with its collaborator, Above & Beyond, launched ALS.AI, launches the personalized drug discovery and biomarker development platform ALS.AI, utilizing the latest advances in deep learning.
KEY FINDINGSEurope has the second largest market share of the DNA sequencing market. Factors, which favor growth of DNA sequencing market, are better healthcare infrastructure, awareness about latest technologies, major biotechnology companies being based in this region and government initiatives for increasing research and development. The global DNA sequencing market is poised to grow during the...
The Scientist is bringing together a panel of experts to share their experience with biomarker discovery and validation for Parkinson's Disease.
Dr. Loeb summarizes a global and one-of-a-kind approach of biomarker and drug discovery using systems biology of human brain tissues.
KEY FINDINGSAsiaPacific market is expected to report good growth in the forecast period due to higher awareness and demand for personalized medicine. Factors, which favor growth of DNA sequencing market, are better healthcare infrastructure, awareness about latest technologies, major biotechnology companies being based in this region and government initiatives for increasing research and developme...
Researchers have identified spermine as a potential biomarker associated with neuropathic forms of mucopolysaccharidoses (MPS), a family of rare metabolic...
Brian BerkAccording to the agency, this is the first time it has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. read more
A potential biomarker protein has been identified that was elevated in rodent models of glaucoma and in fluid taken from...
US FDA has approved a cancer treatment based on a common biomarker, as opposed to the location in the body where the tumour developed.
Gd-IgA1 level may represent a useful biomarker for risk stratification.
Imaging Biomarker Market: By Technology Positron Emission Tomography, Ultrasound, Magnetic Resonance Imaging, Computed Tomography and SinglePhoton Emission Computed Tomography, By Applications By RegionForecast 20162021 [Updated: 23022016] Prices from US
An imaging biomarker is used as a diagnostic mechanism which can be detected through an imaging technology. A biomarker is a biological molecule found in tissue, blood or other body fluids, which mark the presence of a normal or an abnormal process, or of a condition or disease. Thus, these biomarkers are used to monitor responses of the body to a disease. It can also be used for early detection o...